TurtleTree raises $30m in Series A funding

Biotech startup TurtleTree has secured $30 million in the first tranche of its Series A funding to scale up its research and production of functional ingredients found in human milk.

The funding round, which was led by Verso Capital, will be used to expand its portfolio, develop technology and hire new talent. TurtleTree has raised over $40 million to date.

TurtleTree’s CEO, Fengru Lin, said: “Amplified by the relentless backing of parties like Verso Capital, the Series A funds will allow us to scale up our processes and come a huge step closer to creating a new era of sustainable nutrition”.

TurtleTree’s chief strategy officer, Max Rye, added: “The funding received has truly opened up a new world of possibility. We can now set our sights on turning ambitions to reality, starting with our US-based expansion plans and then moving on to the development and manufacture of our first consumer-ready products.”

Last month, TurtleTree opened a new research and development facility in West Sacramento, California.